Amikacin News and Research

RSS

New study reveals effective strategies against drug resistance in hospital-acquired pneumonia treatment

A novel rabbit infection model to investigate meropenem's resistance development.

23 Jan 2024

Understanding antimicrobial resistance in hospital-acquired pneumonia

New research has been published that identifies positive steps towards a better understanding of antimicrobial resistance (AMR), specifically in hospital-acquired pneumonia (HAP).

18 Jan 2024

International clinical trial to evaluate new combinations of generic antibiotics for treating neonatal sepsis

An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.

23 May 2023

New clinical trial gets underway to evaluate new antibiotic combinations for newborns with sepsis

An international clinical trial to evaluate much-needed new antibiotic combinations for newborn babies with sepsis has started in three public hospitals in South Africa and Kenya.

22 May 2023

Revolution in MDR-TB treatment: Shorter all-oral regimens

Researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

6 Apr 2023

Development and testing of a machine-learning-based system for early prediction of antimicrobial susceptibility probability

Researchers developed and tested a machine learning-based clinical decision support system to predict antibiotic resistance.

7 Feb 2023

Manuka honey could cure serious lung infections caused by drug-resistant bacterium

In a recent study published in the journal Microbiology, researchers demonstrated that incorporating Manuka honey into nebulized antibiotic treatment could effectively combat respiratory infections due to Mycobacterium abscessusus, offering a novel new therapeutic strategy for M. abscessus management.

13 Sep 2022

Rarely-used antibiotic could be a safe and affordable treatment for neonatal sepsis

An antibiotic rarely used in infants admitted to hospitals could be a safe and affordable, life-saving treatment for neonatal sepsis, in the face of growing resistance to other drugs, a study finds.

24 Feb 2022

New drug cocktail offers hope to patients with highly drug-resistant tuberculosis

A new three-drug, all-oral, six-month treatment is providing hope to patients in Tajikistan with highly drug-resistant forms of tuberculosis, which until now had limited treatment options and poor prognosis.

3 Feb 2021

Scientists find a potent weapon against antibiotic resistance

Antibiotic resistance is a big threat to global health, and a growing number of infections are now becoming harder to treat. The usual treatments, like antibiotics used to treat them, becomes less effective. Now, a team of researchers may have found a potent weapon against antibiotic-resistant bacteria, which can help treat persistent infections.

15 Aug 2019

Powerful weapon discovered to fight antibiotic resistance in Staphylococcus aureus

Staphylococcus aureus bacteria are a major cause of serious infections that often persist despite antibiotic treatment, but scientists at the UNC School of Medicine have now discovered a way to make these bacteria much more susceptible to some common antibiotics.

14 Aug 2019

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

Insmed reports top-line data from Phase 3 study of new treatment in patients with NTM lung disease

Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study.

13 Sep 2017

Understanding the rise in NTM infections

It is important to keep in mind that nontuberculous mycobacteria are environmental, and so unlike mycobacterial tuberculosis, generally this is not a person to person transmitted disease. The organisms are found universally in water and soil and so most people are exposed on a daily basis.

16 Aug 2017

Study finds high rates of drug resistance to urinary tract infections in Bangladesh

Organisms causing urinary tract infections (UTI) are increasingly proving to be ineffective or showing resistance to drugs that are used to kill the germs. This phenomenon has been increasing worldwide, especially to commonly used antimicrobials (drugs) in children.

3 Aug 2017

New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.

2 May 2017

Novel rapid diagnostic test and shorter treatment with better outcomes may benefit MDR-TB patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

12 May 2016

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of TB

Researchers at University of California, San Diego School of Medicine have documented the accuracy of three new tests for more rapidly diagnosing drug-resistant forms of tuberculosis (TB), which are much harder and more expensive to treat and which, experts say, represent a major threat to global public health.

4 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015